PAX4 promotes PDX1-induced differentiation of mesenchymal stem cells into insulin-secreting cells

Area of Science:

• Stem cell biology
• Endocrinology
• Regenerative medicine

Background:

• Diabetes mellitus poses a significant health burden, with cell replacement therapy limited by the scarcity of donor pancreatic islets.
• Transcription factors like PDX1 and PAX4 are crucial in pancreatic beta-cell development and hold potential for generating insulin-producing cells.

Purpose of the Study:

• To investigate the efficacy of PDX1 and PAX4, delivered via recombinant adenoviruses, in differentiating mesenchymal stem cells (MSCs) into insulin-producing beta-like cells in vitro.
• To assess the impact of PAX4 co-expression with PDX1 on the maturation and functionality of these induced beta-like cells.

Main Methods:

• Mesenchymal stem cells (MSCs) were infected with adenoviruses encoding PDX1 or PDX1 plus PAX4.
• Gene and protein expression were analyzed using RT-PCR, Western blot, and immunofluorescence assays.
• Insulin and C-peptide secretion in response to high glucose was quantified using enzyme-linked immunosorbent assays (ELISAs).

Main Results:

• PDX1 and PAX4 co-expression significantly promoted the differentiation of MSCs into insulin-producing beta-like cells.
• PAX4 enhanced the formation of mature islet-like clusters and improved the functional capacity of PDX1-modified MSCs.
• Virus-infected cells demonstrated glucose-stimulated insulin and C-peptide secretion.

Conclusions:

• The combined use of PAX4 and PDX1 is a potent strategy for generating functional beta-like cells from MSCs.
• This approach offers a promising foundation for developing novel cell-based therapies for diabetes treatment, overcoming limitations of current islet transplantation methods.